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 Abstract 
This paper analyzes the impact of the 2012 legalization of recreational marijuana            
in Washington State on opioid abuse. Using synthetic control methodology, this paper            
finds that the legislation prevented 638 overdose deaths and lead to over 3600 individuals              
seeking treatment for opioid abuse disorders. Due to the large health, social, and             
economic impacts of the opioid epidemic, further research should be conducted into ways             
to reduce the number of opioid prescriptions, the number of opioid overdoses, and opioid              
abuse​ ​generally. 
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 The​ ​Effects​ ​of​ ​Recreational​ ​Marijuana​ ​Legislation​ ​on​ ​the​ ​Opioid​ ​Epidemic​ ​in 
Washington​ ​State 
Steven​ ​Reid​ ​Dickerson​ ​Jr. 
Introduction 
The negative impacts of opioids in the United States cannot be overstated: in 2015              
there were 33,091 overdose deaths caused by opioids, 12,989 of which were due to the               
illicit opioid heroin. The heroin death rate increased 22.2% and total opioid related deaths              
increased 15.5% from 2014 to 2015 (David et al., 2016). On average someone dies from               
an​ ​opioid​ ​related​ ​overdose​ ​about​ ​every​ ​15​ ​minutes. 
Opioids are a class of drug that includes prescription pain relievers (oxycodone,            
hydrocodone, codeine), illegal pain relievers (heroin), and synthetic opioids (fentanyl).          
Opioids treat chronic pain conditions but they also produce a feeling of euphoria. This              
feeling causes many opioids to be highly addictive‒ even when taken as prescribed by a               
physician​ ​(National​ ​Institute​ ​on​ ​Drug​ ​Abuse,​ ​2017). 
The sale of prescription opioid pain relievers quadrupled in the U.S. from 1999 to              
2010 and opioid overdose death rates almost quadrupled over a similar period, from 1999              
to​ ​2008​ ​(Center​ ​for​ ​Disease​ ​Control​ ​and​ ​Prevention,​ ​2011). 
During this same time period, various states began to legalize medical, and            
eventually, recreational marijuana. California was the first state to legalize medical           
marijuana in 1996 and Washington quickly followed suit in 1998 (Eddy, 2010). In             
November of 2012, Washington state legalized recreational marijuana use through ballot           
Initiative​ ​502,​ ​which​ ​took​ ​effect​ ​on​ ​December​ ​1,​ ​2012​ ​(Subbaraman​ ​and​ ​Kerr,​ ​2016). 
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 Thes legalization of medical marijuana opened the door for physicians to           
prescribe medical marijuana to treat chronic pain instead of opioids. Although medical            
literature has not reached a consensus on the possible long term effects of marijuana,              
there is growing consensus that marijuana can be effectively used to treat chronic and              
neuropathic pain (Hill, 2015). Furthermore, physicians have begun to argue that           
marijuana​ ​can​ ​be​ ​explicitly​ ​used​ ​to​ ​treat​ ​opioid​ ​use​ ​disorders​ ​(Hurd,​ ​2017).  
Previous literature has found a causal effect between states with medical           
marijuana legalization and a decrease in the level of opioid overdose death rates             
(Bachhuber et al., 2014; Cerd​à et al., 2016; Shi, 2016). However, a recent study by               
Jacobson et al. (2017) has found that these effects do not hold in states that do not have                  
dispensaries, which facilitate the retail sale of marijuana to qualified patients. This study             
draws upon Pacula et al. (2015), who showed that states with dispensaries had higher              
rates of medical marijuana usage, to conclude that “broader access to medical marijuana             
facilitates substitution of marijuana for powerful and addictive opioids”. My study           
focuses on the effects of the marijuana policy that allows the broadest access to              
marijuana,​ ​the​ ​legalization​ ​of​ ​recreational​ ​marijuana,​ ​on​ ​opioid​ ​abuse. 
However, I am not the first person to study this relationship. Barnett et al. (2017)               
studied the impact of the legalization of recreational marijuana in Colorado on opioid             
overdose rates. They use an interrupted time series model with monthly overdose data             
and find that the recreational marijuana legislation lead to a 6.5% decrease in opioid              
related deaths. I expand upon this result by employing a different empirical strategy to              
study​ ​the​ ​effects​ ​of​ ​recreational​ ​marijuana​ ​in​ ​Washington​ ​State​ ​instead​ ​of​ ​Colorado. 
5 
 This paper provides succinct and relevant analysis on the effects of the            
recreational legalization of medical marijuana in Washington State on opioid abuse,           
treatment, and overdose deaths. This paper employs a synthetic control methodology with            
two commonly used datasets, the Treatment Admissions Episode Data Set (TEDS-A),           
and mortality overdose data provided by the National Vital Statistics System (NVSS) in             
order to estimate the effect of the legislation. I also use summary statistics from the               
National Survey on Drug use and Health (NSDUH) in order to help contextualize and              
corroborate​ ​these​ ​results. 
The legalization of recreational marijuana could lead to a decline in the rates of              
opioid abuse and overdose by allowing individuals to shift away from using opioids to              
using marijuana to treat chronic pain conditions, by allowing individuals to use marijuana             
to lessen the negative effects of withdrawal symptoms, or by further destigmatizing the             
prescription of medical marijuana in place of opioids. However, the legalization of            
recreational marijuana could also lead to an increase in the rates of opioid abuse by               
providing​ ​a​ ​legal​ ​gateway​ ​drug​ ​to​ ​opioids​ ​or​ ​by​ ​destigmatizing​ ​general​ ​drug​ ​usage. 
My analysis finds that recreational marijuana legalization in Washington State          
lead to a reduction in opioid overdoses but an increase in treatment admissions relative to               
a synthetic control group. However, due to the nature of the synthetic control             
methodology, causal inference remains intricate. I expand upon this in the empirical            
strategy and analysis sections. Self-reported opioid usage declines over this time period            
as​ ​well. 
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 This paper is divided into 6 additional sections. The literature summary surveys            
the existing literature base. The data section presents the data sets. The empirical strategy              
section discusses the analysis techniques. The analysis section studies the data. The            
results section summarizes the findings. And the conclusion contextualizes the results and            
offers​ ​a​ ​direction​ ​for​ ​future​ ​research. 
Literature​ ​Summary 
The literature summary is broken up into three sections. The first section analyzes             
the opioid epidemic, the second section presents the history of marijuana laws in the              
United States and Washington, and the third section examines the recent literature on             
how​ ​marijuana​ ​laws​ ​affect​ ​opioid​ ​trends. 
A​ ​History​ ​of​ ​the​ ​Opioid​ ​Epidemic 
The opioid epidemic has many causes. The most direct are the aggressive,            
misrepresentative, and criminal advertising of OxyContin by Purdue Pharma in the 1990s            
and the changing beliefs about pain management in the United States (Lembke, 2012;             
Zee,​ ​2009). 
Beginning in 1996, Purdue Pharma (owners of OxyContin), aggressively         
marketed OxyContin, a sustained release oxycodone preparation (an opioid), to          
physicians around the country and misrepresented the risk of addiction (Maxwell, 2011).            
Purdue Pharma marketed OxyContin as having a risk of addiction at less than 1%, when               
the true risk was much higher. This marketing campaign helped grow OxyContin sales             
from $48 million in 1996 to nearly $1.1 billion in 2000 (Zee, 2009). In 2007, Purdue                
Pharma plead guilty to “misbranding OxyContin, a prescription opioid pain medication,           
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 with the intent to defraud or mislead… as less addictive, less subject to abuse and               
diversion, and less likely to cause tolerance and withdrawal than other medications” and             
paid monetary sanctions totaling $600 million (United States of America v. The Purdue             
Frederick​ ​Company,​ ​Inc.,​ ​Et​ ​Al.,​ ​2007). 
This issue was greatly exacerbated in Florida, and a few other states including             
Texas, by the existence of “pill mills”, profit-motivated rogue pain clinics that            
misprescribed and over prescribed prescription opioids, and “doctor shopping”, where an           
individual receives multiple prescriptions from different providers, in the 2000s (Chen et            
al., 2013; Chakravarthy et al., 2012; Alexander et al., 2016). Through a series of              
Prescription Drug Monitoring Program laws, pill mill laws, and raids carried out by the              
Drug Enforcement Agency, many of these operations have been shut down and opioid             
overdose rates have declined (Boyle et al., 2015; Herter et al., 2014). As of June 2012,                
every state and Washington D.C. had a Prescription Drug Monitoring Program in order to              
help physicians prescribe opioids more cautiously and responsibly, but further research           
needs to be done to judge their effectiveness at reducing opioid abuse and overdoses              
(Gugelmann​ ​et​ ​al,​ ​2012). 
Shifting opinions about how pain should be treated have also contributed to the             
opioid epidemic. Recently, with the improvement of medicine, there has been a paradigm             
shift from pain being a positive sign of vitality to pain being a symptom that doctors                
should aim to totally eliminate (Lembke, 2012). While this is a shift that is hard to                
quantify, it is important to consider when thinking about the incredible amount of             
prescriptions​ ​for​ ​opioids. 
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 There is also an economic component to the opioid epidemic: as the            
unemployment rate increases by 1% then the opioid overdose emergency department visit            
rate has been shown to increase by 3.6% (Hollingsworth, 2017). There were also a              
myriad of other forces, incorrect prescribing practices, accessible legal and illegal           
supplies, and lethargic government responses, that contributed to the opioid epidemic           
(Maxwell,​ ​2011). 
The opioid epidemic wreaks havoc indiscriminately but there are more          
pronounced effects in certain demographic groups. The most common individuals to die            
from a drug overdose are white males between the ages of 25 and 54 (Hedegaard et al.,                 
2017). In 2015, 2 million Americans (12 and older) had a substance use disorder              
involving prescription pain relievers and 591,000 had a substance use disorder involving            
heroin​ ​(Center​ ​for​ ​Behavioral​ ​Health​ ​Statistics​ ​and​ ​Quality,​ ​2016). 
After 2010, the landscape of the opioid epidemic began to change significantly.            
Heroin and fentanyl (a synthetic opioid) have been the major driving forces behind the              
soaring overdose rates (David et al., 2016). The number of heroin-related deaths was             
pretty constant from 2002-2010 but have increased in each subsequent year, possibly as a              
response to a reformulated abuse-deterrent formulation of oxycodone, which lead to a            
decrease in the abuse of oxycodone (Cicero et al., 2012, Dart, et al., 2015). The               
percentage of deaths from drug overdoses involving heroin tripled from 2010 to 2015 and              
the percentage of overdose deaths from synthetic opioids (such as fentanyl and tramadol)             
also tripled over this same time period (a time when total drug overdoses were also               
increasing)​ ​(Hedegaard​ ​et​ ​al.,​ ​2017). 
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 This epidemic has lead to a wide variety of responses at the state and national               
level. In early 2016, Congress passed the 21st Century Cures Act which provided $1              
Billion in new funding to combat the opioid epidemic‒ primarily through increasing            
access to substance use disorder treatment (The White House, 2016), and in 2017, the              
Center for Disease Control and Prevention (CDC) awarded an additional $29 million to             
44 states and the District of Columbia to help combat the opioid epidemic (Center For               
Disease Control and Prevention, 2017). A majority of states have also implemented            
naloxone access laws and good samaritan laws; both these pieces of legislation were             
estimated to reduce opioid-related deaths by 9 to 11%, but the effects of good samaritan               
laws​ ​were​ ​not​ ​statistically​ ​significant​ ​(Argys,​ ​2017). 
The opioid epidemic has had obscene impact in terms of loss of life, but it also                
has impacted the economy as a whole. The opioid epidemic has been shown to have               
strong negative effects on employment-to-population ratios and labor force participation          
rates (Glenn et al., 2017). In 2013, the economic burden of prescription opioid overdose,              
abuse, and dependence was estimated to be $78.6 billion (Florence, 2016), and this             
number​ ​may​ ​have​ ​increased​ ​to​ ​$92​ ​Billion​ ​in​ ​2014​ ​(Meisel​ ​et​ ​al.,​ ​2016). 
The​ ​History​ ​of​ ​Marijuana​ ​Legislation​ ​in​ ​the​ ​United​ ​States 
The first known usage of marijuana in the United States was in 1611 when              
Jamestown settlers used it in hemp production. The usage of marijuana for medical             
purposes soon followed. During the 1800s and early 1900s marijuana was widely            
prescribed by physicians and pharmacists for a variety of illnesses (Chriqui et al., 2002).              
Marijuana became illegal with the Marihuana Tax Act of 1937 and its position was              
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 solidified with the Controlled Substance Act of 1970 (Kamin 2014). As states began to              
legalize marijuana, they created a paradox of legality where marijuana was illegal at the              
federal​ ​level,​ ​but​ ​legal​ ​at​ ​the​ ​state​ ​level​ ​(Grabarsky​ ​2013). 
In contrast to the incredible economic cost of the opioid epidemic, medical and             
recreational marijuana legislation generates huge revenues for States. In 2016          
Washington State and local governments collected $65 million from recreational          
marijuana sales (Washington State Department of Revenue, 2017) and in 2016, Colorado            
State and local governments collected $193 million in taxes from recreational marijuana            
sales​ ​(Colorado​ ​Department​ ​of​ ​Revenue,​ ​2017). 
Although the medical literature has not reached a consensus on the possible long             
term effects of marijuana, there is unambiguous consensus that marijuana is less harmful             
that prescription opioids and there is a growing consensus that marijuana can be             
effectively used to treat pain and neuropathic pain (Hill, 2015). Furthermore, physicians            
have begun to argue that marijuana can be explicitly used to treat opioid use disorders               
(Hurd,​ ​2017). 
There are also some other effects of marijuana legalization that are worth            
considering when making policy decisions. Medical marijuana laws might increase the           
labor supply of older adults‒ which could be particularly important when considering the             
toll the opioid epidemic is taking on the current labor supply (Maclean and Nicholas,              
2016). In general medical marijuana laws have not had particularly negative effects (Hall             
and Weier, 2015). However, medical marijuana legalization is associated with higher           
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 rates of health care visits‒ particularly related to edible marijuana products (Heard et al.,              
2015). 
The​ ​Effect​ ​of​ ​Marijuana​ ​Laws​ ​on​ ​Opioid​ ​Abuse 
Medical marijuana laws have allowed physicians to substitute away from opioid           
prescriptions and shift towards marijuana when treating a variety of medical issues            
(Jacobson et al., 2017). Before 2010, medical marijuana laws had been shown to decrease              
opioid overdoses and other opioid related harm (Bachhuber, et al., 2014, Cerd​à et al.,              
2016, Shi, 2016). However, a recent study concluded that only states with dispensaries,             
which make it easier to obtain medicinal marijuana, experience reductions in opioid            
overdoses​ ​(Jacobson​ ​et​ ​al.,​ ​2017). 
This study by Jacobson et al. (2017) uses a difference-in-differences strategy that            
compares opioid abuse indicators in medical marijuana states versus states where medical            
marijuana is illegal. They use an event study analysis to estimate the effects after              
legalizing medical marijuana to assess the causal impact of the legislation. They find that              
when a state legalizes dispensaries as part of their medical marijuana legislation this leads              
to a decrease in opioid overdoses and a decrease in treatment admissions for opioid              
abuse. Jacobson et al. (2017) use treatment admissions as a proxy for opioid abuse              
instead of analyzing them on their own. I interpret treatment admissions differently and             
will​ ​discuss​ ​this​ ​in​ ​the​ ​results​ ​section. 
A recent study by Barnett et al. (2017) use an interrupted time series model with               
monthly overdose data and find that the 2012 recreational marijuana legalization in            
Colorado lead to a 6.5% in opioid related deaths. However, they do not present a               
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 compelling argument about the causal impact of the recreational marijuana legislation           
because​ ​they​ ​lack​ ​a​ ​reasonable​ ​counter-factual​ ​for​ ​comparison.  
They try to get around this issue by including two states, Nevada and Utah, as               
covariates in their regression analysis. But neither state has similar pre-treatment trends,            
so they do not serve as accurate control groups. Nevada follows a different trend              
particularly over the 2007-2012 period and Utah follows a similar trend but has an              
approximately 60% larger increase in their opioid overdose fatalities over the 2001-2012            
period.  
Because this study fails to effectively control for larger regional or national trends             
in the opioid epidemic, their causal interpretation is tenuous. However, this study does             
control for Colorado’s Prescription Drug Monitoring Program which passed the same           
year as Washington’s Prescription Monitoring Program (Washington State Department of          
Health, 2017). Barnett et al. (2017) found that their results held when Colorado made              
their​ ​Prescription​ ​Drug​ ​Monitoring​ ​Program​ ​mandatory. 
Data 
This paper examines data by state and year on overdose deaths, self-reported data             
on opioid usage, and data for the number of admission to treatment facilities for opioid               
abuse. 
13 
 Opioid​ ​Overdose​ ​Crude​ ​Death​ ​Rate 
The data on overdose deaths is provided through Center for Disease Control’s            
(CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) system. The          1
WONDER multiple cause of death system provides data on overdose deaths from            
1999-2015 by state and year. WONDER uses mortality data provided to the National             
Center for Health Statistics by the Vital Statistics Cooperative Program which uses            
information from all death certificates filed in the fifty states and the District of Columbia               
to generate detailed mortality information. These mortality records include coded          
information​ ​about​ ​cause​ ​of​ ​death. 
In line with Jacobson et al. (2017), I have chosen to use the International              
Classification of Disease 10th revision (ICD-10) codes. I tallied every death record by             
year and by state that included one of the external cause of death and mortality codes,                
X40-X44, X60-64, X85, and Y10-Y14 and the drug identification codes T40.1-T40.4.           
These codes correspond to all types of death (unintentional, suicide, assault, or deaths of              
unclear intent) related to prescription, illicit, or synthetic opioids. From this database, I             
have also chosen to look at the opioid overdose crude death rate (per 100,000              
individuals), as opposed to total number of deaths, in order to adjust for changing              
population​ ​sizes. 
1 ​ ​Further​ ​information​ ​on​ ​WONDER​ ​is​ ​available​ ​at, 
https://wonder.cdc.gov/wonder/help/main.html#​. 
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 Self-Reported​ ​Opioid​ ​Usage 
The data on self-reported drug usage is provided through the National Survey on             
Drug Usage and Health (NSDUH) which is administered SAMHSA. The NSDUH which            
is an annual nationwide survey involving interviews with approximately 70,000          
individuals aged 12 and older. This survey is conducted by a Research Triangle Institute              
(a nonprofit that provides research services) professional who visits each of the selected             
households and administers the NSDUH, which covers a wide variety of drug usage and              
mental health topics. The state estimates in the publicly released survey results are based              2
on a survey-weighted hierarchical Bayes estimation approach and they are generated by            
Markov​ ​Chain​ ​Monte​ ​Carlo​ ​techniques. 
This study uses responses by state and year to a prompt about whether an              
individual uses or has used (in the last year) a pain reliever in any way that was not                  
instructed by a doctor. Unfortunately, the NSDUH is only publicly available by state and              
year starting in 2009 and the SAMHSA stopped asking about pain reliever misuse in              
2014,​ ​so​ ​responses​ ​to​ ​this​ ​question​ ​are​ ​only​ ​available​ ​from​ ​2009​ ​to​ ​2014. 
Treatment​ ​Admissions 
The data for the number of admissions to treatment facilities by state and year for               
opioid abuse is provided through the Treatment Episode Data Set (TEDS-A)           
administered by the Substance Abuse and Mental Health Services Administration          
(SAMHSA). The TEDS-A data set only includes admissions to treatment facilities across            
2 ​ ​Further​ ​information​ ​on​ ​the​ ​NSDUH​ ​available​ ​at, 
https://nsduhweb.rti.org/respweb/project_description.html​. 
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 the country and is accessible through the years 1999-2014. The only facilities that are              
captured in the TEDS-A data set are those that receive state alcohol and/or drug agency               
funds. Furthermore, there are many legal differences across states which affect reporting            
to TEDS-A. ​However, a previous study has found that the TEDS-A data set captures a               3
large​ ​portion​ ​of​ ​all​ ​admissions​ ​(Jacobson​ ​et​ ​al.,​ ​2017). 
From the TEDS-A data set, I include all admissions to treatment facilities for             
methadone addiction (an opioid commonly used in addictions treatment facilities), heroin           
addiction, or a third generic opioid addiction category in my analysis of the overall opioid               
abuse​ ​treatment​ ​admission​ ​rates. 
Empirical​ ​Strategy 
In order to address the causal impact of the recreational marijuana legislation, it is              
important to have a reasonable counterfactual. Unfortunately, the perfect counterfactual          
for comparison is a hypothetical Washington where the recreational marijuana legislation           
failed to pass. This study constructs a synthetic control group to use as the counterfactual               
to​ ​estimate​ ​what​ ​would​ ​have​ ​happened​ ​in​ ​Washington​ ​in​ ​the​ ​absence​ ​of​ ​the​ ​legislation. 
For the synthetic control group, Synthetic Washington, this study uses the           
methodology laid out by Galiani and Quistorff (2016) which builds upon work done by              
Abadie et al. (2010). The synthetic control method is similar to the            
difference-in-differences method but instead of giving equal weighting to each untreated           
group, a new control group is generated that it is a weighted average of the untreated                
3 ​ ​Further​ ​information​ ​on​ ​TEDS-A​ ​is​ ​available​ ​at, 
https://wwwdasis.samhsa.gov/webt/information.htm​. 
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 groups which is designed to closely resemble the treatment group (Washington) in the             
pre-treatment​ ​period​ ​(2012​ ​and​ ​earlier)​ ​(Galiani​ ​and​ ​Quistorff,​ ​2016).  
The synthetic control is constructed to very closely resemble Washington State up            
until the year the recreational marijuana legislation took effect. Technically this synthetic            
control group is constructed in order to minimize root mean squared prediction error             
between the synthetic control and the treatment group. To project the synthetic control             
group into the post-treatment period (2013-present), the observed value (for overdoses or            
treatment admissions) in each state is multiplied by its weight in the synthetic control              
group​ ​(Galiani​ ​and​ ​Quistorff,​ ​2016). 
The critical identifying assumption in my analysis is that in the post-treatment            
period the synthetic control group would have similar outcomes to Washington if the             
recreational marijuana legislation didn’t pass. I will assess the specific validity of this             
claim with regards to particular outcomes in my analysis section. But, generally, because             
the synthetic control group has a similar trend to Washington in the pre-treatment period,              
I assume that the synthetic control group has a similar trend to Washington, if the               
recreational​ ​marijuana​ ​legislation​ ​was​ ​not​ ​passed,​ ​in​ ​the​ ​post-treatment​ ​period. 
The validity of this assumption, that synthetic Washington is a good predictor of             
Washington without the recreational marijuana legislation, is addressed by running          
placebo tests. This means that a synthetic control group for each of the other 47 states                
(excluding Oregon and Colorado) is generated based on the pre-treatment data and then             
the synthetic control group for each state is compared to the observed values of the state                
in the post-treatment period. However, none of these states had the same recreational             
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 marijuana legislation, so the placebo test checks how well the synthetic control            
methodology does at predicting outcomes in the other 47 states where no treatment             
actually occurred. This assumption is measured by calculating a p-value which is the             
fraction of states that have larger absolute deviations from their synthetic control group             
than Washington has from its synthetic control group, Synthetic Washington (Galiani and            
Quistorff,​ ​2016).  
However, this is not a perfect method because many states have implemented            
policies aimed at reducing opioid abuse in the 2012-2015 period so that the observed              
difference between the synthetic control group and the “treated” state is larger than it              
actually would have been without any interventions. This would cause the observed            
p-value to go up because many states are likely experiencing larger than expected             
deviations from their predicted values. So it is likely that the p-values in this study are                
overestimates​ ​of​ ​the​ ​true​ ​value. 
Finally, due to the possible spillover effects between Washington State and           
Oregon and the legalization of recreational marijuana in Colorado, this study excludes            
Oregon and Colorado from the synthetic control groups. The spillover effect exist            
because when marijuana became recreationally legal in Washington State, it became           
easier to obtain for Oregon residents. So the effects of the legalization of recreational              
marijuana in Washington would also have some effect in Oregon. Similarly with            
Colorado, because Colorado legalized recreational marijuana the same year as          
Washington State, it is probable that similar effects would exist in both states‒ so              
Colorado​ ​would​ ​not​ ​make​ ​an​ ​appropriate​ ​counterfactual. 
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 Analysis 
This section is broken up into analysis about the opioid overdose crude death rate,              
self-reported​ ​opioid​ ​usage,​ ​and​ ​treatment​ ​admissions​ ​related​ ​to​ ​opioid​ ​abuse. 
Opioid​ ​Overdose​ ​Crude​ ​Death​ ​Rates 
Washington’s opioid overdose crude death rate increased steadily from 1999 to           
2008 and then saw a slight decline, leveling off in 2011. Between 2012 and 2014 there                
was a decline and then in 2015 there was a sharp increase in the opioid overdose crude                 
death rate. Figure 1 shows Washington’s opioid overdose crude death rate (per 100,000)             
from 1999-2015. Without any control group, it is impossible to tell what the effect of the                
recreational​ ​marijuana​ ​legislation​ ​was​ ​on​ ​the​ ​opioid​ ​crude​ ​death​ ​rate. 
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 In the absence of this legislation, the opioid overdose crude death rate may have              
increased or decreased significantly and that would be impossible to measure without a             
control group. Washington had a high relative opioid overdose crude death rate from             
1999 to the late 2000s but then in the 2010s many states’s opioid overdose crude death                
rates began to surpass Washington’s. Figure 2 shows Washington and the other 47 state’s              
opioid​ ​overdose​ ​crude​ ​death​ ​rates. 
 
I created Synthetic Washington to serve as the control group to assess the impact              
of the recreational marijuana legislation. Synthetic Washington is the weighted average           
of the other 47 states (excluding Oregon and Colorado) that minimizes the root mean              
squared prediction errors of Washington compared to Synthetic Washington over the           
1999-2012 pre-treatment period. Louisiana, California, Nevada, Connecticut, and        
20 
 Maryland are the states with the largest weights in Synthetic Washington and many states              
that​ ​have​ ​dissimilar​ ​trends​ ​have​ ​a​ ​weight​ ​of​ ​0. 
Figure 3 presents the trends of Washington and Synthetic Washington over the            
1999-2015 period. Washington and Synthetic Washington follow similar pre-policy         
trends but diverge after 2012. This divergence is pronounced. Synthetic Washington has a             
much​ ​larger​ ​opioid​ ​overdose​ ​crude​ ​death​ ​rate​ ​than​ ​the​ ​rate​ ​observed​ ​rate​ ​in​ ​Washington.  
 
The estimated effect of the recreational marijuana legislation is that it reduced the             
opioid overdose crude death rate by 2.5961 people (per 100,000) in 2013, 3.089 people              
(per 100,000) in 2014, and 3.3305 people (per 100,000) in 2014. That implies that this               
legislation saved 181 lives in 2013, 218 lives in 2014, and 239 lives in 2015. Figure 4                 
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 explicitly shows this difference between Washington and Synthetic Washington’s opioid          
overdose​ ​crude​ ​death​ ​rates. 
 
Concluding a causal inference is intricate. The p-values for the three           
post-legislation years are 0.13 in 2013, 0.19 in 2014, and 0.29 in 2015, which implies that                
13% of states had a larger deviation from their synthetic control group in 2013, 19% in                
2014, and 29% in 2015. Figure 5 illustrates each state's deviation from its synthetic              
control​ ​group.  
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For many of the states with large post-treatment deviations, their synthetic control            
groups do not accurately match the state in the pre-treatment period. For many of these               
outlier states, the root mean squared prediction error, a term that calculates the total              
deviation in the pre-treatment period, are between 3 and 10 times larger than the root               
mean squared prediction error for Synthetic Washington. For these states, the synthetic            
control groups do not predict the pre-treatment trends well, so I do not expect that they                
would​ ​predict​ ​the​ ​post-treatment​ ​trends​ ​well​ ​either. 
In order to overcome this issue, I tried running the placebo tests again after              
removing states with root mean squared prediction errors which were larger than a             
multiple of Washington’s root mean squared prediction error. I tried removing states that             
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 had root mean squared prediction errors that were 1000%, 500%, 300%, 200% and 150%              
larger than Washington’s root mean squared prediction errors from the placebo test. The             
p-values​ ​were​ ​remarkably​ ​robust​ ​to​ ​this​ ​sort​ ​of​ ​deletion.  
The only restriction that yielded a significant difference was the 150% restriction.            
After limiting the placebo test to states that had less than 150% of Washington’s root               
mean squared prediction error, there were 25 remaining comparison states and the            
p-values were 0 for 2013, 0.08 for 2014, and 0.20 for 2015 which implies that none of the                  
25 states had larger deviations than Washington in 2013, 8% of the states that were               
involved in the placebo test had larger deviations than Washington in 2014, and 20% of               
these​ ​states​ ​had​ ​larger​ ​deviations​ ​in​ ​2015. 
Of the states that had reasonably accurate synthetic control groups (root mean            
squared prediction errors less than 150% of Washington’s), Washington had the largest            
deviation from their synthetic control group in the first year after the legalization of              
recreational marijuana and one of the largest deviations in the 2nd and 3rd years after               
passage. This shows that the decrease in Washington’s crude death rate was likely a              
result​ ​of​ ​the​ ​legislation​ ​instead​ ​of​ ​random​ ​variation​ ​or​ ​prediction​ ​error. 
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 Self-Reported​ ​Opioid​ ​Usage 
Due to the data limitations and availability for self-reported opioid usage           
discussed in the Data section, it is not possible to conduct analysis using synthetic control               
groups,​ ​so​ ​this​ ​paper​ ​only​ ​provides​ ​basic​ ​rates​ ​which​ ​are​ ​presented​ ​in​ ​Figure​ ​5. 
For the years available, self-reported misuse of prescription painkillers declined in           
Washington State. Whether this is due to the recreational marijuana legislation is hard to              
tell because it is hard to establish the pre-treatment trends. Furthermore, this decline may              
not represent a decline in opioid abuse because it might only be capturing a shift away                
from​ ​prescription​ ​opioid​ ​abuse​ ​to​ ​illicit​ ​opioid​ ​abuse. 
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 Opioid​ ​Abuse​ ​Treatment​ ​Admissions 
This section employs a synthetic control methodology to analyze the impact of the             
recreational marijuana legislation on treatment admissions. Treatment admissions in         
Washington steadily increased over the 2000-2010 period, with a dip in the mid 2000s.              
This increase slowed over the 2010-2013 period and then, in 2014, the number of              
treatment​ ​admissions​ ​grew​ ​by​ ​nearly​ ​2000.​ ​Figure​ ​7​ ​shows​ ​this​ ​graphically​ ​below. 
 
In a similar fashion to the opioid overdose crude death rate, the effect of the               
recreational marijuana legislation on treatment admissions is impossible to measure          
without a control group. In order to get around this issue, I constructed a synthetic control                
group from the 47 other states. Of the 47 other states, shown in Figure 8, Washington’s                
number of treatment admissions was higher than most states over the entire 2000-2014             
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 period. There is also a large variance in the number of treatment admissions across              
states‒​ ​that​ ​is​ ​likely​ ​caused​ ​by​ ​differences​ ​in​ ​population​ ​size,​ ​amongst​ ​some​ ​other​ ​factors. 
 
The synthetic control group, synthetic Washington, is different than the synthetic           
control group used for the previous analysis. This control group has been generated in              
order to match the pre-treatment trend for Washington State in regards to treatment             
admissions for opioid abuse. Illinois, Mississippi, Michigan, Arkansas, Connecticut, and          
Maine receive the largest weights in Synthetic Washington. Figure 9 presents a graph of              
Washington and Synthetic Washington for 2000-2014. They are incredibly similar in the            
pre-treatment​ ​period​ ​and​ ​then​ ​diverge​ ​in​ ​the​ ​post-treatment​ ​period. 
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Relative to Synthetic Washington, Washington State in the post-treatment period          
has a large increase in treatment admissions. Figure 10 shows Washington’s number of             
treatment admission relative to Synthetic Washington. In 2013 there were 990 more            
treatment admissions than in Synthetic Washington, and in 2014 there were 2,637 more             
treatment​ ​admissions. 
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The p-values for these two years are 0.28 in 2013 and 0.20 in 2014, which imply                
that 28% of states had larger deviations from their synthetic control groups in 2013 and               
20% of states had larger deviations from their synthetic control groups in 2014. This              
appears to convey a relatively high-degree of uncertainty about the true predicting power             
of the synthetic control group methodology with respect to the number of opioid abuse              
related treatment admissions. However, as is shown in Figure 11, many of the states with               
large deviations also have very large root mean squared prediction errors so they do not               
have similar accuracy to Synthetic Washington, so therefore, they should not be            
considered​ ​in​ ​the​ ​placebo​ ​test. 
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The states with large root mean squared prediction errors have synthetic control            
groups that are bad at matching the pre-treatment trends, so I do not expect these               
synthetic control groups to do a good job predicting the outcomes in the post-treatment              
period. So I would like to only include states in the placebo tests that have relatively                
small (relative to Washington) root mean squared prediction errors because these are the             
states​ ​that​ ​are​ ​likely​ ​to​ ​have​ ​more​ ​accurate​ ​post-treatment​ ​predictive​ ​power. 
I tried restricting the placebo tests to states with 1000%, 500%, 300%, 200%, and              
then 150% of the root mean squared prediction error that Washington and Synthetic             
Washington have. When I made this criterion more restrictive, the p-values for            
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 Washington became smaller. The p-values dropped from 0.28 to 0.08 in 2013 and from              
0.20​ ​to​ ​0.04​ ​in​ ​2014​ ​as​ ​more​ ​states​ ​were​ ​exclude​ ​from​ ​the​ ​placebo​ ​tests. 
There were 23 states left in the placebo test when the states, whose Synthetic              
control groups had root mean squared prediction errors greater than 150% of Synthetic             
Washington’s root mean squared prediction error, were removed. Of the states that had             
reasonably accurate synthetic control groups, only 8% had larger deviations from their            
synthetic control groups in 2013 and only 4% of these states had larger deviations from               
their synthetic control group in 2014. This shows that the increase in the number of               
opioid abuse related treatment admissions in Washington was likely a result of this             
legislation​ ​instead​ ​of​ ​random​ ​variance​ ​or​ ​prediction​ ​error. 
Results 
At the end of this sections I have included a subsection, titled “Limitations and              
Critiques”, where I provide responses to a couple possible critiques and explicitly discuss             
the​ ​limitations​ ​of​ ​this​ ​analysis. 
In terms of both opioid related overdoses as well as self-reported usage there has              
been a decline. However, of these two indicators, this paper only shows that the              
recreational marijuana legislation had a causal impact on opioid overdoses. There is            
insufficient data to draw a reasonable conclusion about the causal impact about the             
legislation’s effect on self-reported usage. However, due to the causal impact on the             
opioid overdoses, it is likely that there was also a causal impact on the self-reported               
usage. Further, it is reasonable to assume that if less individuals are overdosing on              
opioids, then less individuals are also abusing opioids. This is congruous with the decline              
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 in both the opioid overdoses as well as the self-reported usage. This is a large and likely                 
unforeseen​ ​benefit​ ​from​ ​recreational​ ​marijuana​ ​legalization​ ​in​ ​Washington​ ​State. 
Despite the decline in these two indicators, treatment admissions have a sharp            
increase in the post-legalization period, particularly in 2014. Previous literature relied on            
treatment admissions as a proxy for opioid usage. However, with the presence of             
mortality statistics as well as limited data available from the NSDUH, this paper does not               
interpret treatment admissions as an indicator of opioid usage. This paper interprets            
treatment​ ​admissions​ ​as​ ​treatment​ ​admissions,​ ​which​ ​are​ ​a​ ​benefit​ ​to​ ​society. 
This is because the number of treatment admissions is likely a function of many              
variables, one of which is definitely the rate of drug usage‒ but this is not the only                 
variable that affects the number of treatment admissions. Treatment admissions continued           
to increase in the mid/late 2000s even when the opioid overdose crude death rate              
remained constant (or even decreased). So, it is clear that the opioid overdose crude death               
rate is not the only factor which affects the number of treatment admissions. Social              
stigma, quality of treatment, financial conditions (funding and insurance structures), and           
a wide variety of more nuanced factors, all of which the legalization of recreational              
marijuana​ ​could​ ​impact,​ ​also​ ​affect​ ​the​ ​number​ ​of​ ​treatment​ ​admissions. 
It should be noted that recent studies have shown that cannabis can be used in the                
treatment of opioid abuse disorders (Hurd, 2016). The passage of recreational marijuana            
in Washington expanded treatment options available to treatment facilities, could have           
helped to de-stigmatize medical marijuana usage at large, and could have helped opioid             
abusers​ ​begin​ ​self-treating​ ​before​ ​going​ ​to​ ​enter​ ​a​ ​formal​ ​treatment​ ​facility. 
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 Regardless of the link, ​Ceteris paribus​, an increase in treatment admissions would            
have a positive influence on opioid abuse and overdoses. By this rationale, because             
recreational marijuana legislation has not lead to an increase in opioid usage, the increase              
in​ ​treatment​ ​admissions​ ​should​ ​be​ ​interpreted​ ​as​ ​a​ ​positive​ ​effect​ ​of​ ​this​ ​legislation. 
Limitations​ ​and​ ​Critiques 
One possible critique is that there are no control variables in this analysis. This              
could lead to omitted variable bias. However, when testing different synthetic control            
groups, using the male/female population ratio, median household-income, percent of          
individuals who are white, and other demographic factors at the annual and state level,              
there are only very small changes to the outcomes of Washington relative to Synthetic              
Washington for opioid overdoses. The changes in the effects on treatment admissions are             
larger,​ ​but​ ​not​ ​more​ ​than​ ​1,600​ ​treatment​ ​admissions. 
Another possible critique is that Washington State passed a Prescription          
Monitoring Program in 2007 that took effect in 2011 (Washington State Department of             
Health, 2017), so some of the decrease in opioid related overdoses or increase in              
treatment admissions observed in the 2013-2015 period could be due to this legislation.             
However, this is unlikely because previous literature has shown that similar Prescription            
Drug Monitoring Programs have had little to no effect on drug overdoses (Desai 2011),              
since 2010 the main drivers of the opioid epidemic have been the synthetic opioid              
fentanyl and the illicit opioid heroin (David et al., 2016), and, because this legislation was               
passed in 2007 and took effect in 2011, there were many years for doctors to adjust their                 
prescription habits to comply with the legislation before the implementation date.           
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 Furthermore there were two years where this legislation could have impacted overdose            
rates and the number of treatment admissions before the recreational marijuana           
legislation​ ​took​ ​effect. 
One limitation is that part of the decrease in opioid overdoses is likely partly              
explainable by the increase in treatment admissions. However, treatment admissions have           
been steadily increasing over the entire 2000-2014 period, but there have been no large              
declines in opioid abuse overdoses over the same period. Furthermore, even if the             
increase in treatment admissions explained the decline in opioid overdoses, there is no             
other factor that would likely have lead to an increase in treatment admissions for opioid               
abuse.​ ​Hence,​ ​this​ ​legislation​ ​would​ ​still​ ​have​ ​a​ ​large​ ​positive​ ​impact. 
A third limitation is the amount of data; due to the recent nature of this epidemic                
and legislation there limited data available. This study cannot analyze the long term             
impacts of the recreational marijuana legislation and it remains challenging to create a             
control​ ​group​ ​due​ ​to​ ​the​ ​limited​ ​pre-treatment​ ​data. 
Conclusion 
Previous literature showed a link between medical marijuana and a reduction in            
opioid abuse, predicate on medicinal marijuana being available through dispensaries.          
These studies use the opioid overdose crude death rate as well as the number of treatment                
admissions as proxies for the total amount of opioid abuse. Additionally, Barnett et al.              
(2017) employed an interrupted time series model to show that Colorado’s legalization of             
recreational​ ​marijuana​ ​in​ ​2012​ ​lead​ ​to​ ​a​ ​decrease​ ​in​ ​the​ ​opioid​ ​overdose​ ​crude​ ​death​ ​rate. 
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 I expand upon this literature by using a synthetic control group methodology in             
Washington State to study the impact of their 2012 legalization of recreational marijuana             
on opioid overdoses and treatment admissions in Washington State. In terms of the opioid              
overdose crude death rate, my result corroborate Barnett et al. (2017) and show that the               
legalization of recreational marijuana lead to a decline in the opioid overdose crude death              
rate​ ​in​ ​Washington​ ​State. 
But, in terms of the treatment admissions, my results contradict previous findings.            
Previous literature has shown that medical marijuana laws lead to a reduction in             
treatment admissions but my study finds that the legalization of recreational marijuana            
lead to an increase in the number of treatment admissions. Because the opioid overdose              
crude death rate was declining over the post-treatment time period, I propose that             
treatment​ ​admissions​ ​should​ ​be​ ​seen​ ​as​ ​a​ ​benefit,​ ​instead​ ​of​ ​as​ ​a​ ​proxy​ ​for​ ​opioid​ ​abuse. 
Further research should be conducted in order to determine the linkage between the             
number of treatment admissions and the opioid overdose crude death rate, the long-term             
impacts of recreational marijuana legislation, and the impact of this policy across            
different​ ​states​ ​and​ ​times. 
The opioid epidemic is and has been one of the most pressing societal and policy               
issues facing our nation. It is ruining lives, destroying families, and killing thousands             
every year. Due to the incredible societal harm and death toll that the opioid epidemic is                
causing, it is imperative to continue analysis of and find effective responses to every facet               
of​ ​the​ ​opioid​ ​epidemic. 
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